The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood cancer called multiple myeloma that has recurred in patients who had ...

It may be a year later than originally planned, but Regeneron Pharmaceuticals Inc. is set to commercialize Lynozyfic (linvoseltamab) in the U.S. following FDA approval for use in adults with relapsed ...

Regeneron had previously been the winning bidder in a bankruptcy auction for virtually all of 23andMe’s assets, but it's now lost out after bidding was reopened.

AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase ...

By removing such B cells, CAR-T therapy can stop disease progression or help reset the immune system. Though the therapy is approved only for cancer, research suggests that it could also help ...

Pharmalittle: We’re reading about FDA probing deaths after Sarepta treatment, a Regeneron plan for charities, and more ...

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

Nippon Steel has completed its acquisition of U.S. Steel, the companies said on Wednesday, more than a year after it was first announced. Soon after Nippon announced its plans to acquire U.S ...